larotaxel

Small moleculeexperimental

Larotaxel is a drug of the taxane type that has been used experimentally in chemotherapy. — Wikipedia

Clinical trial activity

8 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Apr 1, 2004 (NCT00081796)

Timeline

2000s

Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Jan 1, 2004
Earliest Phase 3 Sponsor(trial)
Jan 1, 2006
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)O[C@H]1C(=O)[C@]23C[C@H]2C[C@H]2OC[C@@]2(OC(C)=O)[C@H]3[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C1C2(C)C

Mol. weight: 831.91 g/mol
Lipinski Ro5: 2 violation(s)
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No

Oral

Parenteral

Topical

Sources

WikipediaLarotaxel ↗
ChEMBLCHEMBL4279455 ↗

Also known as

larotaxel
larotaxel
larotaxel
larotaxel
xrp9881
xrp9881
xrp9881
xrp 9881
xrp-9881

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00625664	Phase 3	Feb 1, 2008	Sanofi
NCT00485979	Phase 2	Jun 1, 2007	Sanofi, St. Louis University
NCT00417209	Phase 3	Dec 1, 2006	Sanofi
NCT00387907	Phase 2	Oct 1, 2006	Harvard University, Sanofi
NCT00327743	Phase 1/Phase 2 (Phase 2)	Aug 1, 2006	Sanofi
NCT00386685	Phase 2	Jul 1, 2006	Sanofi, University of Toulouse
NCT00087958	Phase 2	Aug 1, 2004	Sanofi
NCT00081796	Phase 3	Apr 1, 2004	Sanofi

Showing 8 of 8 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Sanofi	For profit	8	8	2	2004
Harvard University	Academic/Hospital	1	0	1	2006
St. Louis University	Academic/Hospital	1	0	1	2007
University of Toulouse	Academic/Hospital	1	0	1	2006

4 organizations

Page 1 / 1